This article is more than 5 years old. Information may no longer be current.
Eylea sales up in first quarter
Click Here to Manage Email Alerts
Eylea net product sales totaled $854 million in the United States for the first quarter, up 9% over the same quarter last year, according to a Regeneron press release.
In the first quarter of 2016, Eylea (aflibercept) injection sales totaled $781 million.
Regeneron also reported total revenues for the quarter of $1.319 billion, an increase of 10% from 2016’s $1.201 billion.
GAAP net income was $249 million, or $2.36 per basic share and $2.16 per diluted share, in the first quarter of 2017, compared to a net income of $181 million, or $1.74 per basic share and $1.59 per diluted share, in the first quarter of 2016.
Research and development costs were $470 million in the first quarter of 2016 and $507 million in the first quarter of 2017, with the increase partly attributed to an increase in clinical trial costs for fasinumab and REGN2810, which are agents under study for treating osteoarthritis and cancer, respectively.